Revenue Comparison for Pfizer Over the Last 5 Years Including 2023

Pfizer's revenue: A rollercoaster ride over five years.

__timestampPfizer Inc.
Monday, January 1, 201853647000000
Tuesday, January 1, 201951750000000
Wednesday, January 1, 202041908000000
Friday, January 1, 202181288000000
Saturday, January 1, 2022100330000000
Sunday, January 1, 202358496000000
Loading chart...

Unleashing the power of data

Pfizer's Revenue Journey: A Five-Year Retrospective

Pfizer Inc., a titan in the pharmaceutical industry, has experienced a dynamic revenue trajectory over the past five years. In 2018, Pfizer's revenue stood at approximately $53.6 billion. However, by 2020, the company faced a dip, with revenues dropping to around $41.9 billion, marking a decline of nearly 22% from 2018. This downturn was short-lived, as 2021 saw a remarkable recovery, with revenues surging by 94% to approximately $81.3 billion, largely driven by the global demand for COVID-19 vaccines. The upward trend continued into 2022, with revenues peaking at $100.3 billion, a 23% increase from the previous year. However, 2023 brought a recalibration, with revenues settling at $58.5 billion, reflecting a 42% decrease from the 2022 high. This data underscores Pfizer's resilience and adaptability in a rapidly changing global landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
29 Nov 2024